Skip to main content
Equibles
CAMP logo

CAMP · Camp4 Therapeutics Corp

Track CAMP — free

Use CAMP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CAMP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.25 -0.09 (-2.07%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$266.70M
Shares
62.75M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.25 Open$4.46 Day$4.21–4.54 52W close$2.28–7.13 Avg vol 30d273K Short int1.2M · 1.9% float · 4.2d Short vol52% Last earningsNov 21, 2024 DataOct 2024–Sep 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.22M
Trailing 12 months
Net income (TTM)
−$107.24M
Trailing 12 months
Revenue growth YoY
+18.8%
Year over year
Operating margin
-1,254.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$86.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+187.4%
Year over year · more shares
Price change (1Y)
+55.6%
Trailing year
Short interest
1.9%
Latest settlement · 4.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg +3%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 41%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −15%
trailing
YTD return −31%
this year
Relative strength −33%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+30% holders QoQ · +23 funds added
Insider flow Distributing
Net -$2.4M over 90 days · 33% sells
Short interest Falling
1.89% of float · ▼ -7.0% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
61 holders — near 1-yr high, broad support
Squeeze score 48
elevated · 0–100
Fundamentals
Strong
Revenue growth +437%
Y/Y
EPS growth +76%
Y/Y
Free cash flow $-29.8M
Quant / Vol
risk profile
Very High
Volatility 116%
annualized · 1-yr
Max drawdown −58%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
+3% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
41% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+30% holders QoQ · +23 funds added
Insider flow Distributing
Net -$2.4M over 90 days · 33% sells
Short interest Falling
1.89% of float · ▼ -7.0% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
61 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $4 · 41% Range high $7
vs 200-day avg -6% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CAMP
Camp4 Therapeutics Corp
this stock
$266.70M -30.7% +436.5% — 1.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
61
% held
66.4%
Net QoQ
+1.9M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
48
View
Short & Settlement
Short Interest Falling
Shares short
1.2M
Days to cover
4.2d
Change
-89.9K sh
View
Short Volume
Short vol %
52%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
294.8K
Value
$1.3M
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
55.7%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
-$2.4M
Buyers / Sellers
4 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$3.5M
Net income (FY)
$-80.4M
EPS diluted
$-2.65
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
15
View
Exempt Offerings
Offering
Indefinite
Filed
Jun 21, 2022
View
Earnings & Events
Earnings Calls
Last call
Apr 13, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CAMP -5.4% -5.6% -15.0% +7.3% -30.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.2% -3.8% -32.8% +7.7% -42.8%
Key facts CIK 1736730 CUSIP 13463J101 13F (30d) 40 filings 40 filers Visit website Investor relations